Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 8/20 | 0.63 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | BCR | P11274 | 1/20 | 0.59 |
| ▸ | PRKCA | P17252 | 1/20 | 0.59 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.59 |
| ▸ | CDK4 | P11802 | 2/20 | 0.57 |
| ▸ | CAMK2D | Q13557 | 6/20 | 0.55 |
| ▸ | EIF2AK2 | P19525 | 2/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | PLK1 | P53350 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5105343 | 0.85 | CDK2 (0.69) | CDK2ABL1PRKCAPRKCDCDK4 | |
| SCHEMBL6104420 | 0.83 | CDK2 (0.59) | CDK2ABL1BCRPRKCAPRKCD | |
| SCHEMBL6594423 | 0.81 | ABL1 (0.62) | CDK2ABL1BCRPRKCAPRKCD | |
| SCHEMBL6104927 | 0.78 | CDK2 (0.73) | CDK2CDK4CDK1 | |
| SCHEMBL1684802 | 0.77 | CDK2 (1.00) | CDK2ABL1BCRPRKCAPRKCD | |
| SCHEMBL1684747 | 0.77 | CDK2 (0.73) | CDK2ABL1BCRPRKCAPRKCD | |
| SCHEMBL6103727 | 0.77 | CDK2 (0.81) | CDK2CDK4CDK1 | |
| SCHEMBL6594301 | 0.76 | ABL1 (0.58) | CDK2ABL1BCRPRKCAPRKCD | |
| SCHEMBL3600187 | 0.76 | ABL1 (0.65) | CDK2ABL1BCRPRKCAPRKCD | |
| SCHEMBL2328157 | 0.76 | CAMK2D (0.70) | CDK2ABL1BCRPRKCAPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1269813-C | Imidazolo-5-yl-2-anilino-pyrimidines as agents for inhibition of cell proliferation | ASTRAZENECA AB (SE) | 2006-08-16 | — | — | CN | disclosed |
| US-20060004033-A1 | Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| US-6969714-B2 | Imidazolo-5-YL-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation | ASTRAZENECA AB (SE) | 2005-11-29 | — | — | US | disclosed |
| EP-1351958-B1 | IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| US-20040014776-A1 | Imidazolo-5-YL-2anilino-pyrimidines as agents for the inhibition of the cell proliffration | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | US | disclosed |
| CN-1452620-A | Imidazolo-5-yl-2-anilino-pyrimidines as agents for inhibition of cell proliferation | ASTRAZENECA AB (CH) | 2003-10-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004033-A1 | Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation | MKI67, CCNI, CCNT1 | CDK2 13/4885ABL1 173/4885BCR 2384/4885 |
| US-20040014776-A1 | Imidazolo-5-YL-2anilino-pyrimidines as agents for the inhibition of the cell proliffration | CCNI, TYMP, MKI67 | CDK2 11/4885ABL1 822/4885BCR 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.